KHK and metabolic dysfunction-associated steatotic liver disease: ,16 Recently, phase 2 studies using a KHK inhibitor in adults with MASLD have shown reduced hepatic steatosis with acceptable safety and tolerability (NCT03256526, NCT03969719).17